Literature DB >> 9301981

Distribution and expression of beta-lactamase genes among Aeromonas spp.

T R Walsh1, R A Stunt, J A Nabi, A P MacGowan, P M Bennett.   

Abstract

Clinical and environmental isolates of Aeromonas spp. (20 Aeromonas caviae, 33 Aeromonas veronii and 21 Aeromonas hydrophila) were examined for their ability to yield mutants derepressed for beta-lactamase production and for the distribution of the three chromosomally encoded beta-lactamase genes, ampS and cepS from A. veronii bv. sobria and cphA from A. hydrophila. Of these isolates, 100% and 96% of the isolates from A. hydrophila and A. caviae, respectively, yielded beta-lactamase derepressed mutants but only 38% of A. veronii isolates yielded the resistant phenotype at 37 degrees C. However, when tested at 30 degrees C, all isolates gave rise to the derepressed mutants, indicating a temperature effect on the control mechanism. All mutants had significantly higher beta-lactamase activity against ampicillin, oxacillin, cephaloridine and imipenem. Hybridization studies with cloned aeromonas beta-lactamase genes indicated that the cephalosporinase gene, cepS, is almost ubiquitous for the three species tested. The cphA gene cross-hybridized with all isolates of A. veronii and A. hydrophila but not to A. caviae isolates. In contrast, hybridization studies using ampS revealed that only 25% of A. caviae, 45% of A. veronii and 38% of A. hydrophila tested carried the ampS gene or one closely homologous to it. Nonetheless, strains that failed to hybridize with ampS showed two serine beta-lactamases when analysed by isoelectric focusing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301981     DOI: 10.1093/jac/40.2.171

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.

Authors:  D M Livermore; M W Carter; S Bagel; B Wiedemann; F Baquero; E Loza; H P Endtz; N van Den Braak; C J Fernandes; L Fernandes; N Frimodt-Moller; L S Rasmussen; H Giamarellou; E Giamarellos-Bourboulis; V Jarlier; J Nguyen; C E Nord; M J Struelens; C Nonhoff; J Turnidge; J Bell; R Zbinden; S Pfister; L Mixson; D L Shungu
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Bacteremia caused by Aeromonas species [corrected] complex in the Caribbean Islands of Martinique and Guadeloupe.

Authors:  Patrick Hochedez; Emilie Hope-Rapp; Claude Olive; Muriel Nicolas; Gilles Beaucaire; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

3.  Aeromonas Isolates from Fish and Patients in Tainan City, Taiwan: Genotypic and Phenotypic Characteristics.

Authors:  Chi-Jung Wu; Wen-Chien Ko; Nan-Yao Lee; Shu-Li Su; Chia-Wen Li; Ming-Chi Li; Yi-Wei Chen; Yu-Cheng Su; Cing-Ying Shu; Yu-Tzu Lin; Po-Lin Chen
Journal:  Appl Environ Microbiol       Date:  2019-10-16       Impact factor: 4.792

4.  Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.

Authors:  B Lamy; F Laurent; A Kodjo; F Roger; E Jumas-Bilak; H Marchandin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-27       Impact factor: 3.267

Review 5.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

6.  Alterations in Peptidoglycan Cross-Linking Suppress the Secretin Assembly Defect Caused by Mutation of GspA in the Type II Secretion System.

Authors:  Elizabeth M Vanderlinde; Timothy G Strozen; Sara B Hernández; Felipe Cava; S Peter Howard
Journal:  J Bacteriol       Date:  2017-03-28       Impact factor: 3.490

7.  In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.

Authors:  W C Ko; H C Lee; Y C Chuang; S H Ten; C Y Su; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis.

Authors:  Samuel Bellais; Delphine Girlich; Amal Karim; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy.

Authors:  W C Ko; H M Wu; T C Chang; J J Yan; J J Wu
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

Review 10.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.